Aytu Biopharma, Inc. splits its revenue into 9 lines in its filings. The largest line in fiscal 2026, which ended Jun 30, 2026 was ADHD Portfolio at $45.8 million, 80% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
FY 2020
Jun 30, 2020
|
FY 2020
Jun 30, 2019
|
FY 2018
Jun 30, 2018
|
FY 2017
Jun 30, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
58
|
66
|
65
|
107
|
97
|
66
|
28
|
7
|
4
|
3
|
| Adhd Portfolio |
—
|
—
|
58
+23.3%
share 88.6%
|
47
share 43.6%
|
—
|
—
|
—
|
—
|
—
|
—
|
| ADHD Portfolio |
46
-20.4%
share 79.6%
|
58
share 86.7%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Attention Deficit Hyperactivity Disorder Portfolio |
—
|
—
|
—
|
—
|
43
+293.8%
share 44.3%
|
11
share 16.6%
|
—
|
—
|
—
|
—
|
| Consumer Health Portfolio |
—
|
—
|
—
|
—
|
36
+7.9%
share 36.8%
|
33
share 50.2%
|
—
|
—
|
—
|
—
|
| Pediatric Portfolio |
—
|
—
|
—
|
—
|
16
+29.3%
share 16.6%
|
12
share 18.9%
|
—
|
—
|
—
|
—
|
| EXXUA Portfolio |
7
share 11.4%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| The Pediatric Portfolio |
5
-41.4%
share 8.9%
|
9
+20.5%
share 13.2%
|
7
-71.3%
share 11.2%
|
25
share 23.6%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Other Product Portfolio |
—
|
—
|
—
|
—
|
2
-76.7%
share 2.3%
|
9
share 14.3%
|
—
|
—
|
—
|
—
|
| Product And Service Other |
0
-2.7%
share 0.1%
|
0
-68.9%
share 0.1%
|
0
-92.4%
share 0.2%
|
2
share 1.5%
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AYTU (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Denver, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1385818
- Former names
- AYTU BIOSCIENCE, INC (until Mar 22, 2021); Rosewind CORP (until Jun 8, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.